SYNLOGIC, INC. Increase Decrease In Operating Lease Liability
SYNLOGIC, INC. (SYBX) reported Increase Decrease In Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-03-12
- SYNLOGIC, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $0.00.
- SYNLOGIC, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was $0.00.
- SYNLOGIC, INC. increase decrease in operating lease liability for the quarter ending 2025-06-30 was $0.00.
- SYNLOGIC, INC. increase decrease in operating lease liability for the quarter ending 2025-03-31 was $0.00.
- SYNLOGIC, INC. increase decrease in operating lease liability for fiscal 2025 was $0.00.
- SYNLOGIC, INC. increase decrease in operating lease liability for fiscal 2024 was -$12.42M.
- SYNLOGIC, INC. increase decrease in operating lease liability for fiscal 2023 was -$4.09M.
- SYNLOGIC, INC. increase decrease in operating lease liability for fiscal 2022 was -$3.90M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | -$11.23M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | -$11.23M derived: sum of 3 quarters · filed 2026-03-12 | -$12.42M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$11.23M derived: sum of 2 quarters · filed 2025-11-13 | -$12.42M 10-Q · filed 2025-11-13 | -$13.48M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$11.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$12.42M 10-Q · filed 2025-08-07 | -$13.48M derived: sum of 3 quarters · filed 2025-08-07 | -$14.51M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.18M 10-Q · filed 2025-05-08 | -$2.25M derived: sum of 2 quarters · filed 2025-05-08 | -$3.27M derived: sum of 3 quarters · filed 2025-05-08 | -$4.28M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$2.09M derived: sum of 2 quarters · filed 2025-03-06 | -$3.10M derived: sum of 3 quarters · filed 2025-03-06 | -$4.09M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.04M derived: sum of 2 quarters · filed 2024-11-12 | -$3.03M 10-Q · filed 2024-11-12 | -$4.00M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.00M 10-Q · filed 2024-08-08 | -$2.97M derived: sum of 3 quarters · filed 2024-08-08 | -$3.91M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$994.00K 10-Q · filed 2024-05-14 | -$1.96M derived: sum of 2 quarters · filed 2024-05-14 | -$2.90M derived: sum of 3 quarters · filed 2024-05-14 | -$4.15M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$966.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$1.91M derived: sum of 2 quarters · filed 2024-03-19 | -$3.16M derived: sum of 3 quarters · filed 2024-03-19 | -$3.90M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$941.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.19M derived: sum of 2 quarters · filed 2023-11-09 | -$2.93M 10-Q · filed 2023-11-09 | -$3.67M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.99M 10-Q · filed 2023-08-10 | -$2.72M derived: sum of 3 quarters · filed 2023-08-10 | -$3.43M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$739.00K 10-Q · filed 2023-05-11 | -$1.47M derived: sum of 2 quarters · filed 2023-05-11 | -$2.18M derived: sum of 3 quarters · filed 2023-05-11 | -$2.83M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$733.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$1.44M derived: sum of 2 quarters · filed 2023-03-29 | -$2.10M derived: sum of 3 quarters · filed 2023-03-29 | -$2.70M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$704.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$1.36M derived: sum of 2 quarters · filed 2022-11-10 | -$1.97M 10-Q · filed 2022-11-10 | -$2.55M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$658.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$1.26M 10-Q · filed 2022-08-11 | -$1.84M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$606.00K 10-Q · filed 2022-05-12 | -$1.19M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$2.00M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | -$1.42M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |